Asterias Biotherapeutics Inc (NYSE:AST) has been given a $12.00 price objective by research analysts at HC Wainwright in a research report issued to clients and investors on Monday. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 275.00% from the company’s current price.

A number of other research firms have also commented on AST. Zacks Investment Research lowered shares of Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Monday, April 3rd. Laidlaw started coverage on shares of Asterias Biotherapeutics in a research note on Tuesday, April 4th. They set a “buy” rating and a $12.00 price objective for the company.

Shares of Asterias Biotherapeutics (NYSE:AST) traded up 4.69% during trading on Monday, reaching $3.35. 53,162 shares of the company’s stock were exchanged. The firm’s market capitalization is $165.03 million. The company’s 50-day moving average price is $3.27 and its 200 day moving average price is $3.73. Asterias Biotherapeutics has a 52 week low of $2.30 and a 52 week high of $5.80.

Asterias Biotherapeutics (NYSE:AST) last posted its quarterly earnings data on Tuesday, March 28th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. Asterias Biotherapeutics had a negative net margin of 312.79% and a negative return on equity of 58.31%. The business had revenue of $1.75 million for the quarter, compared to the consensus estimate of $2.81 million. Analysts predict that Asterias Biotherapeutics will post ($0.72) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/06/19/asterias-biotherapeutics-inc-ast-given-a-12-00-price-target-at-hc-wainwright.html.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.